Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders.

Tytuł:
Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders.
Autorzy:
Rasool MF; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Rehman AU; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.; Department of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
Khan I; Department of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
Latif M; Department of Zoology, Division of Science and Technology, University of Education, Lahore, Pakistan.
Ahmad I; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Shakeel S; Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi, Pakistan.
Sadiq M; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Hayat K; Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.
Shah S; Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
Ashraf W; Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Majeed A; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Hussain I; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Hussain R; Department of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
Źródło:
PloS one [PLoS One] 2023 Jan 24; Vol. 18 (1), pp. e0276277. Date of Electronic Publication: 2023 Jan 24 (Print Publication: 2023).
Typ publikacji:
Observational Study; Journal Article
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Drug Interactions*
Chronic Disease*
Humans ; Cross-Sectional Studies ; Prospective Studies ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Risk Factors
References:
Rev Invest Clin. 2011 Nov-Dec;63(6):564-73. (PMID: 23650669)
Arch Med Sci. 2014 Oct 27;10(5):920-32. (PMID: 25395943)
Res Social Adm Pharm. 2008 Dec;4(4):355-66. (PMID: 19064242)
Expert Rev Pharmacoecon Outcomes Res. 2020 Aug;20(4):343-354. (PMID: 32530725)
Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):661-672. (PMID: 31596632)
Eur J Gen Pract. 2008;14(1):23-9. (PMID: 18464169)
Am J Health Syst Pharm. 1999 Aug 1;56(15):1524-9. (PMID: 10478990)
Eur J Clin Pharmacol. 2015 Feb;71(2):131-42. (PMID: 25529225)
Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):517-528. (PMID: 31401898)
Br J Clin Pharmacol. 2015 Oct;80(4):808-17. (PMID: 25677107)
Pharm World Sci. 2010 Dec;32(6):815-21. (PMID: 20922479)
BMC Health Serv Res. 2018 Oct 10;18(1):762. (PMID: 30314487)
Singapore Med J. 2012 Aug;53(8):526-31. (PMID: 22941130)
Int J Clin Pharm. 2013 Jun;35(3):455-62. (PMID: 23483444)
Clin Interv Aging. 2014 Dec 01;9:2079-86. (PMID: 25489239)
J Community Hosp Intern Med Perspect. 2016 Sep 07;6(4):31758. (PMID: 27609720)
Basic Clin Pharmacol Toxicol. 2018 May;122(5):512-516. (PMID: 29143454)
Int J Clin Pharmacol Ther. 2007 Dec;45(12):643-53. (PMID: 18184532)
J Clin Pharm Ther. 2005 Feb;30(1):13-20. (PMID: 15659000)
Sci Rep. 2021 Nov 19;11(1):22598. (PMID: 34799609)
J Pharm Pharm Sci. 2009;12(3):266-72. (PMID: 20067703)
Int J Pharm Pract. 2021 Dec 4;29(6):580-586. (PMID: 34651641)
Pharmacoecon Open. 2021 Mar;5(1):35-44. (PMID: 32291727)
PLoS One. 2017 Mar 8;12(3):e0173466. (PMID: 28273128)
Front Public Health. 2020 Nov 19;8:531038. (PMID: 33330300)
Pharmaceutics. 2020 Jul 30;12(8):. (PMID: 32751436)
Drug Saf. 2006;29(1):79-90. (PMID: 16454536)
Int J Clin Pract. 2017 Oct;71(10):. (PMID: 28869702)
Int J Qual Health Care. 2013 Oct;25(5):590-8. (PMID: 23771745)
Int J Environ Res Public Health. 2022 Apr 13;19(8):. (PMID: 35457564)
Int J Clin Pharm. 2013 Oct;35(5):753-62. (PMID: 23715760)
Int J Environ Res Public Health. 2020 Apr 27;17(9):. (PMID: 32349339)
J Pharm Pharm Sci. 2006;9(3):427-33. (PMID: 17207423)
Br J Clin Pharmacol. 2000 Aug;50(2):172-5. (PMID: 10930970)
Qual Saf Health Care. 2004 Aug;13(4):306-14. (PMID: 15289635)
Drug Saf. 2015 Feb;38(2):197-206. (PMID: 25556085)
Int J Environ Res Public Health. 2020 Mar 25;17(7):. (PMID: 32218355)
Saudi Pharm J. 2020 Feb;28(2):155-160. (PMID: 32042253)
PLoS One. 2022 Jul 29;17(7):e0271587. (PMID: 35905133)
Br J Clin Pharmacol. 2014 Aug;78(2):202-17. (PMID: 24283967)
Int J Clin Pharm. 2016 Feb;38(1):119-26. (PMID: 26511945)
Eur J Health Econ. 2020 Mar;21(2):181-194. (PMID: 31564007)
J Pharm Pract. 2018 Feb;31(1):58-65. (PMID: 29278992)
J Clin Epidemiol. 1994 Nov;47(11):1245-51. (PMID: 7722560)
J Crit Care. 2018 Feb;43:1-6. (PMID: 28822348)
Entry Date(s):
Date Created: 20230124 Date Completed: 20230127 Latest Revision: 20230918
Update Code:
20240105
PubMed Central ID:
PMC9873175
DOI:
10.1371/journal.pone.0276277
PMID:
36693042
Czasopismo naukowe
Patients suffering from chronic diseases are more likely to experience pDDIs due to older age, prolonged treatment, severe illness and greater number of prescribed drugs. The objective of the current study was to assess the prevalence of pDDIs and risk factors associated with occurrence of pDDIs in chronic disease patients attending outpatient clinics for regular check-ups. Patients suffering from diabetes, chronic obstructive pulmonary disease (COPD), stroke and osteoporosis were included in the study. This study was a cross sectional, observational, prospective study that included 337 patients from outpatient clinics of respiratory ward, cardiac ward and orthopedic ward of Nishter Hospital Multan, Pakistan. The mean number of interactions per patient was 1.68. A greater risk for occurrence of pDDI was associated with older age ≥ 60 years (OR = 1.95, 95% CI = 1.44-2.37, p<0.001); polypharmacy (≥ 5 drugs) (OR = 3.74, 95% CI 2.32-4.54, p<0.001); overburden (OR = 2.23, 95% CI = 1.64-3.16, p<0.01); CCI score (OR = 1.28, 95% CI = 1.04-1.84, p<0.001); multiple prescribers to one patient (OR = 1.18, 95% CI = 1.06-1.41, p<0.01); and trainee practitioner (OR = 1.09, 95% CI = 1.01-1.28, p<0.01). Old age, polypharmacy, overburden healthcare system, higher comorbidity index, multiple prescribers to one patient and trainee practitioner were associated with increased risk of occurrence of pDDIs in chronic disease patients.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Rasool et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies